Clinical Trial

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

Study acronym: HS-20117
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-29.
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Trial Details
NCT Number NCT06621563
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
Enrollment 780 participants
Start Date 2024-12-14
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-09